Advertisement
Screener

Crinetics Pharmaceuticals, Inc. (CRNX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-02-26

  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-02-26
2025-03-310.00%
10-Q · filed 2025-05-08
2024-12-310.00%
10-K · filed 2026-02-26
2024-09-300.00%
10-Q · filed 2024-11-12
0.00%
10-Q · filed 2024-11-12
2024-06-300.00%
10-Q · filed 2024-08-08
0.00%
10-Q · filed 2024-08-08
2024-03-310.00%
10-Q · filed 2025-05-08
2023-12-310.00%
10-K · filed 2026-02-26
2023-09-300.00%
10-Q · filed 2024-11-12
0.00%
10-Q · filed 2024-11-12
2023-06-300.00%
10-Q · filed 2024-08-08
0.00%
10-Q · filed 2024-08-08
2023-03-310.00%
10-Q · filed 2024-05-09
2022-12-310.00%
10-K · filed 2025-02-27
2022-09-300.00%
10-Q · filed 2022-11-14
2022-06-300.00%
10-Q · filed 2022-08-12
2022-03-310.00%
10-Q · filed 2022-05-12
2021-12-310.00%
10-K · filed 2022-03-30
2021-09-300.00%
10-Q · filed 2021-11-05
2021-06-300.00%
10-Q · filed 2021-08-10
2021-03-310.00%
10-Q · filed 2021-05-06
2020-12-310.00%
10-K · filed 2021-03-30
2020-09-300.00%
10-Q · filed 2020-11-06
2020-06-300.00%
10-Q · filed 2020-08-07
2020-03-310.00%
10-Q · filed 2020-05-08
2019-12-310.00%
10-K · filed 2020-03-09
2019-09-300.00%
10-Q · filed 2019-11-12
2019-06-300.00%
10-Q · filed 2019-08-13
2019-03-310.00%
10-Q · filed 2019-05-13
2018-09-300.00%
10-Q · filed 2018-11-13
2018-06-300.00%
10-Q · filed 2018-08-30